Targeting the Chemokine CXCR3 Reduces Alzheimer's Disease

by Dr. Trupti Shirole on  December 17, 2014 at 9:55 AM Mental Health News
RSS Email Print This Page Comment
Chemokine CXCR3, protein that regulates inflammation and the immune response, can be used as a potential therapeutic target for Alzheimer's disease (AD), according to scientists from the University of Bonn. The study indicates that activation of the CXCL10 receptor, CXCR3, contributes to AD pathology.
 Targeting the Chemokine CXCR3 Reduces Alzheimer's Disease
Targeting the Chemokine CXCR3 Reduces Alzheimer's Disease
Advertisement

AD is the most common form of dementia and is characterized by the formation of amyloid plaques throughout the brain. In both patients with AD and mouse AD models, the CXCL10 is found in high concentrations in the brain and may contribute to development of AD. Using a murine model of AD, Michael Heneka and colleagues found that mice lacking CXCR3 had reduced amyloid plaque formation. Also, loss of CXCR3 signaling in AD mice attenuated behavioral deficits.

Advertisement
The study is published in 'Journal of Clinical Investigation'.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Diet and Alzheimer´s Disease Genetics of Alzheimer´s disease 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive